ESCRS - PP19.07 - Long-Term Refractive And Tolerance Results Of The Hydrophobic Clareon® Intraocular Lens. The Clarte Study : About 277 Cases

Long-Term Refractive And Tolerance Results Of The Hydrophobic Clareon® Intraocular Lens. The Clarte Study : About 277 Cases

Published 2022 - 40th Congress of the ESCRS

Reference: PP19.07 | Type: Free paper | DOI: 10.82333/5ddh-ry07

Authors: Corinne Dot* 1 , Hugo Bouvarel 1 , Jeremy Billant 1 , Helene Plas 1 , Lucas Sejournet 1 , Raphael Bernier 1 , Antoine Levron 1 , Emilie Agard 1

1Desgenettes Hospital,LYON,France

Purpose

To analyze the long-term refractive and tolerance results of the hydrophobic Clareon® intraocular lens (IOL).

Setting

A retrospective monocentric study conducted in France in real life, on Clareon® IOLs implanted consecutively between July 2017 and December 2019.

Methods

The power of the IOL was evaluated by using the IOL Master 700® (Zeiss) for emmetropia with the SRK/T formula except for hyperopic patients where the multiformula function was preferred. The A constante used was 119.3. The first postoperative refraction was performed 1 month after surgery. A part of these patients have been evaluated 1,2 and 3 years after the surgery. In this last subgroup, visual acuity and safety (transparency and % of Nd:YAG capsulotomy) were assessed. Glistening and PCO were graded by the same operator under pupil dilatation.

Results

277 eyes were enrolled. The mean age of the patients was 75,15 years +/-12. One month after surgery, the mean UCVA was 0,87 +/-0,16. Two third of the patients (61%) had an UCVA superior or equal to 1(logMar 0) and 84,5% superior to 0,8 (logMar 0,1). We have assessed 143 patients three years after surgery: the mean UCVA was 0,89 +/- 0,07. The analysis of the transparency of Clareon® did not reveal any glistening (grade 0) in 95,1% of patients. No PCO was observed in 52,1%. PCO was clinically significant (requiring a capsulotomy) in 5/143 of patients (3,5%) at 3 years. The patient status revealed in all of these 5 cases intraocular pathology or general diseases. 

Conclusions

The refractive results are excellent and maintained 3 years after surgery. The glistening-free status is confirmed. The low level of capsulotomy highlights a very good tolerance and stability of this new IOL.

Work supported by as an Investigator-initiated Trial grant funded by Alcon (IIT#67572681)